HC Wainwright Estimates RenovoRx’s Q4 Earnings (NASDAQ:RNXT)

RenovoRx, Inc. (NASDAQ:RNXT) – Research analysts at HC Wainwright reduced their Q4 2027 earnings per share estimates for RenovoRx in a report released on Friday, November 6th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of ($0.01) per share for the quarter, down from their prior forecast of $0.01. The consensus estimate for RenovoRx’s current full-year earnings is ($0.24) per share.

RNXT has been the topic of several other reports. Wall Street Zen downgraded shares of RenovoRx from a “hold” rating to a “sell” rating in a research note on Monday. Weiss Ratings raised shares of RenovoRx from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, September 2nd. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $8.50.

RenovoRx Price Performance

Shares of NASDAQ:RNXT opened at $1.18 on Monday. RenovoRx has a 12-month low of $0.70 and a 12-month high of $2.59. The business has a 50-day moving average price of $1.53 and a 200 day moving average price of $1.11.

RenovoRx (NASDAQ:RNXT) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.01). The business had revenue of $1.07 million during the quarter, compared to analyst estimates of $1.06 million. RenovoRx had a negative net margin of 621.71% and a negative return on equity of 135.11%.

Institutional Trading of RenovoRx

An institutional investor recently bought a new position in RenovoRx stock. T3 Companies LLC acquired a new position in shares of RenovoRx, Inc. (NASDAQ:RNXT) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 96,800 shares of the company’s stock, valued at approximately $151,000. T3 Companies LLC owned about 0.21% of RenovoRx at the end of the most recent quarter. 3.10% of the stock is owned by institutional investors and hedge funds.

RenovoRx Company Profile

RenovoRx, Inc is a clinical-stage biopharmaceutical company developing targeted treatments for solid tumors. The company’s approach is based on its Trans-Arterial Micro-Perfusion (TAMP) platform, which is designed to deliver chemotherapy directly into tumor tissue through the arterial system while limiting exposure to surrounding healthy tissue.

RenovoRx’s lead investigational product, RenovoCath, is a localized drug-delivery system intended to support the administration of anticancer therapies to tumors.